Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 672931, 5 pages
http://dx.doi.org/10.1155/2015/672931
Research Article

The Correlation between Aquaporin-4 Antibody and the Visual Function of Patients with Demyelinating Optic Neuritis at Onset

1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China
2Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

Received 12 December 2014; Revised 25 April 2015; Accepted 27 April 2015

Academic Editor: Biju B. Thomas

Copyright © 2015 Hui Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Optic Neuritis Study Group, “Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial,” Ophthalmology, vol. 115, no. 6, pp. 1079.e5–1082.e5, 2008. View at Publisher · View at Google Scholar
  2. V. A. Lennon, T. J. Kryzer, S. J. Pittock, A. S. Verkman, and S. R. Hinson, “IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel,” Journal of Experimental Medicine, vol. 202, no. 4, pp. 473–477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Takahashi, K. Fujihara, I. Nakashima et al., “Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre,” Brain, vol. 130, no. 5, pp. 1235–1243, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Wingerchuk, V. A. Lennon, C. F. Lucchinetti, S. J. Pittock, and B. G. Weinshenker, “The spectrum of neuromyelitis optica,” The Lancet Neurology, vol. 6, no. 9, pp. 805–815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Banwell, S. Tenembaum, V. A. Lennon et al., “Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders,” Neurology, vol. 70, no. 5, pp. 344–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Petzold, S. Pittock, V. Lennon, C. Maggiore, B. G. Weinshenker, and G. T. Plant, “Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 1, pp. 109–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Costa, G. Arrambide, M. Tintore et al., “Value of NMO-IgG determination at the time of presentation as CIS,” Neurology, vol. 78, no. 20, pp. 1608–1611, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Jarius, J. Frederikson, P. Waters et al., “Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis,” Journal of the Neurological Sciences, vol. 298, no. 1-2, pp. 158–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. H. Levin, J. L. Bennett, and A. S. Verkman, “Optic neuritis in neuromyelitis optica,” Progress in Retinal and Eye Research, vol. 36, pp. 159–171, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Long, W. Qiu, X. Hu et al., “Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders,” Clinical Neurology and Neurosurgery, vol. 114, no. 8, pp. 1131–1134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. K. H. Chan, J. S. C. Kwan, P. W. L. Ho, J. W. M. Ho, A. C. Y. Chu, and D. B. Ramsden, “Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays,” Journal of Neuroinflammation, vol. 7, article 50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Lai, G. Tian, T. Takahashi, W. Liu, L. Yang, and X. Zhang, “Neuromyelitis optica antibodies in patients with severe optic neuritis in China,” Journal of Neuro-Ophthalmology, vol. 31, no. 1, pp. 16–19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Li, Y. Zhang, Z. Yi, D. Huang, and S. Wei, “Frequency of autoantibodies and connective tissue diseases in chinese patients with optic neuritis,” PLoS ONE, vol. 9, no. 6, Article ID e99323, 2014. View at Publisher · View at Google Scholar
  14. M. Takagi, K. Tanaka, T. Suzuki, A. Miki, M. Nishizawa, and H. Abe, “Anti-aquaporin-4 antibody-positive optic neuritis,” Acta Ophthalmologica, vol. 87, no. 5, pp. 562–566, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Matiello, V. A. Lennon, A. Jacob et al., “NMO-IgG predicts the outcome of recurrent optic neuritis,” Neurology, vol. 70, no. 23, pp. 2197–2200, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mochizuki, A. Hayashi, S. Hisahara, and S. Shoji, “Steroid-responsive Devic's variant in Sjogren's syndrome,” Neurology, vol. 54, no. 6, pp. 1391–1392, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Kitley, M. I. Leite, I. Nakashima et al., “Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan,” Brain, vol. 135, no. 6, pp. 1834–1849, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Jarius, F. Aboul-Enein, P. Waters et al., “Antibody to aquaporin-4 in the long-term course of neuromyelitis optica,” Brain, vol. 131, no. 11, pp. 3072–3080, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. L. Galetta and W. T. Cornblath, “Should most patients with optic neuritis be tested for neuromyelitis optica antibodies and should this affect their treatment?” Journal of Neuro-Ophthalmology, vol. 30, no. 4, pp. 376–379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Palace, M. I. Leite, A. Nairne, and A. Vincent, “Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers,” Archives of Neurology, vol. 67, no. 8, pp. 1016–1017, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Kleiter, K. Hellwig, A. Berthele et al., “Failure of natalizumab to prevent relapses in neuromyelitis optica,” Archives of Neurology, vol. 69, no. 2, pp. 239–245, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-H. Min, B. J. Kim, and K. H. Lee, “Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder,” Multiple Sclerosis, vol. 18, no. 1, pp. 113–115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Jarius, K. Ruprecht, B. Wildemann et al., “Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients,” Journal of Neuroinflammation, vol. 9, article 14, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. D. M. Wingerchuk, W. F. Hogancamp, P. C. O'Brien, and B. G. Weinshenker, “The clinical course of neuromyelitis optica (Devic's syndrome),” Neurology, vol. 53, no. 5, pp. 1107–1114, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. R. M. Papais-Alvarenga, S. C. Carellos, M. P. Alvarenga, C. Holander, R. P. Bichara, and L. C. S. Thuler, “Clinical course of optic neuritis in patients with relapsing neuromyelitis optica,” Archives of Ophthalmology, vol. 126, no. 1, pp. 12–16, 2008. View at Publisher · View at Google Scholar · View at Scopus